OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Safety and efficacy of jaktinib (a novelJAK inhibitor) in patients with myelofibrosis who are relapsed or refractory to ruxolitinib: Asingle‐arm ,open‐label , phase 2, multicenter study
Yi Zhang, Qike Zhang, Qingchi Liu, et al.
American Journal of Hematology (2023) Vol. 98, Iss. 10, pp. 1579-1587
Open Access | Times Cited: 6
Yi Zhang, Qike Zhang, Qingchi Liu, et al.
American Journal of Hematology (2023) Vol. 98, Iss. 10, pp. 1579-1587
Open Access | Times Cited: 6
Showing 6 citing articles:
Managing Myelofibrosis: Matching Advances in Treatments With Clinical Unmet Needs
Chaoyi Wei, Hein Than, Feng‐Ju Huang, et al.
Hematological Oncology (2025) Vol. 43, Iss. S1
Open Access
Chaoyi Wei, Hein Than, Feng‐Ju Huang, et al.
Hematological Oncology (2025) Vol. 43, Iss. S1
Open Access
Efficacy, safety, and survival findings after long‐term follow‐up of ZGJAK002 : A phase 2 study comparing jaktinib at 100 mg twice daily (BID ) and 200 mg once daily (QD ) in patients with myelofibrosis
Yi Zhang, Hu Zhou, Zhongxing Jiang, et al.
American Journal of Hematology (2024) Vol. 99, Iss. 4, pp. 774-779
Open Access | Times Cited: 2
Yi Zhang, Hu Zhou, Zhongxing Jiang, et al.
American Journal of Hematology (2024) Vol. 99, Iss. 4, pp. 774-779
Open Access | Times Cited: 2
The application of JAK inhibitors in the peri-transplantation period of hematopoietic stem cell transplantation for myelofibrosis
Zerong Wang, Xuelian Jin, Jiajia Zeng, et al.
Annals of Hematology (2024) Vol. 103, Iss. 9, pp. 3293-3301
Open Access
Zerong Wang, Xuelian Jin, Jiajia Zeng, et al.
Annals of Hematology (2024) Vol. 103, Iss. 9, pp. 3293-3301
Open Access
Advances in pharmacotherapy for myelofibrosis: what is the current state of play?
Mario Tiribelli, Gianluca Morelli, Massimiliano Bonifacio
Expert Opinion on Pharmacotherapy (2024) Vol. 25, Iss. 6, pp. 743-754
Closed Access
Mario Tiribelli, Gianluca Morelli, Massimiliano Bonifacio
Expert Opinion on Pharmacotherapy (2024) Vol. 25, Iss. 6, pp. 743-754
Closed Access
What Is on the Horizon for Treatments in Idiopathic Pulmonary Fibrosis?
Teng Moua, Misbah Baqir, Jay H. Ryu
Journal of Clinical Medicine (2024) Vol. 13, Iss. 21, pp. 6304-6304
Open Access
Teng Moua, Misbah Baqir, Jay H. Ryu
Journal of Clinical Medicine (2024) Vol. 13, Iss. 21, pp. 6304-6304
Open Access
Long-term risks of cardiovascular-specific mortality among myeloproliferative neoplasms patients
Meiling Tang, Ying Chen, Yanying Zhou, et al.
Therapeutic Advances in Hematology (2024) Vol. 15
Open Access
Meiling Tang, Ying Chen, Yanying Zhou, et al.
Therapeutic Advances in Hematology (2024) Vol. 15
Open Access
Evaluation of gecacitinib vs hydroxyurea in patients with intermediate-2 or high-risk myelofibrosis: final analysis results from a randomized phase 3 study
Yi Zhang, Hu Zhou, Shanshan Suo, et al.
Blood Cancer Journal (2024) Vol. 14, Iss. 1
Open Access
Yi Zhang, Hu Zhou, Shanshan Suo, et al.
Blood Cancer Journal (2024) Vol. 14, Iss. 1
Open Access
